# US 2026/0077038 A1 · Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077038 A1
- Document ID: US20260077038A1
- Status: Published application
- Kind: A1
- Application number: 19/402,500
- Filed: 2025-11-26
- Published: 2026-03-19
- Earliest claimed: 2022-05-25
- Assignees: Akagera Medicines, Inc.
- Applicants: Akagera Medicines, Inc.
- Inventors: Daryl C. Drummond; Dmitri B. Kirpotin; Mark E. Hayes; Alexander Koshkaryev; Ross B. Fulton
- Web page: https://patentgrep.com/patent/US20260077038A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/575: {humoral response}
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

## Claims

### Claim 1

A nucleic acid lipid nanoparticle (LNP) composition targeting a mRNA nucleic acid encapsulated in lipidic nanoparticles to human dendritic cells, the lipidic nanoparticles consisting of:
a. an anionic phospholipid in a total amount of 5 mol % of the total lipid content of the LNP composition, and selected from the group consisting of phosphatidylglycerol (PG) or phosphatidyl-L-Serine (PS);
b. a neutral phosphatidylcholine (PC) lipid in a total amount of 5 mol % of the total lipid content of the LNP composition;
c. a PEG-containing conjugated lipid in a total amount of 0.5-2.5 mol % of the total lipid content of the LNP composition;
d. an ionizable cationic lipid of Formula (II) in a total amount of 40-65 mol % of the total lipid content of the LNP composition, and at a N/P ratio of 3 to 8 relative to the mRNA nucleic acid,
wherein: Y is a 1,3-dioxalane comprising gem di-substitution with two identical lipid hydrocarbon chains at the 2-position; n is an integer 2, 3 or 4; and each of R10 and R12 is independently methyl; and
e. cholesterol.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the anionic phospholipid is a phosphatidylglycerol (PG).

### Claim 3 (depends on 2)

The composition of claim 2, wherein the PG anionic phospholipid is selected from the group consisting of: distearoylphosphatidylglycerol (DSPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol (DOPG), and dimyristoylphosphatidylglycerol (DMPG).

### Claim 4 (depends on 3)

The composition of claim 3, wherein the PC lipid is selected from the group consisting of: distearoylphosphatidylcholine (DSPC) and hydrogenated soy phosphatidylcholine (HSPC).

### Claim 5 (depends on 4)

The composition of claim 4, wherein the PEG-containing conjugated lipid is selected from the group consisting of: PEG (2000)-dimyristoylglycerol (PEG-DMG), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DLPE), and PEG (2000)-dilauroylglycerol (PEG-DLG).

### Claim 6 (depends on 5)

The composition of claim 5, wherein the PG anionic phospholipid is distearoylphosphatidylglycerol (DSPG) and the PC lipid is distearoylphosphatidylcholine (DSPC).

### Claim 7 (depends on 6)

The composition of claim 6, wherein the PEG-containing conjugated lipid is PEG (2000)-dimyristoylglycerol (PEG-DMG).

### Claim 8 (depends on 7)

The composition of claim 7, wherein n is 3.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the anionic phospholipid is a phosphatidyl-L-Serine (PS).

### Claim 10 (depends on 9)

The composition of claim 9, wherein the PS anionic phospholipid is selected from the group consisting of: dipalmitoylphosphatidyl-L-serine (DPPS) and distearoylphosphatidyl-L-serine (DSPS).

### Claim 11 (depends on 10)

The composition of claim 10, wherein the PC lipid is selected from the group consisting of: distearoylphosphatidylcholine (DSPC) and hydrogenated soy phosphatidylcholine (HSPC).

### Claim 12 (depends on 11)

The composition of claim 11, wherein the PEG-containing conjugated lipid is selected from the group consisting of: PEG (2000)-dimyristoylglycerol (PEG-DMG), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DLPE), and PEG (2000)-dilauroylglycerol (PEG-DLG).

### Claim 13 (depends on 12)

The composition of claim 12, wherein the PS anionic phospholipid is dipalmitoylphosphatidyl-L-serine (DPPS).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the PEG-containing conjugated lipid is PEG (2000)-dimyristoylglycerol (PEG-DMG).

### Claim 15 (depends on 14)

The composition of claim 14, wherein n is 3.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the neutral PC lipid is selected from the group consisting of: distearoylphosphatidylcholine (DSPC) and hydrogenated soy phosphatidylcholine (HSPC).

### Claim 17 (depends on 1)

The composition of claim 1, wherein the PEG-containing conjugated lipid is selected from the group consisting of: PEG (2000)-dimyristoylglycerol (PEG-DMG), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DLPE), and PEG (2000)-dilauroylglycerol (PEG-DLG).

### Claim 18 (depends on 1)

The composition of claim 1, wherein n is 3 or 4.

### Claim 19 (depends on 1)

The composition of claim 1, wherein:
a. the anionic phospholipid is dipalmitoylphosphatidyl-L-serine (DPPS);
b. the neutral phosphatidylcholine (PC) lipid is distearoylphosphatidylcholine (DSPC);
c. the PEG-containing conjugated lipid is PEG (2000)-dimyristoylglycerol (PEG-DMG); and
d. n is 3.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the lipidic nanoparticles encapsulate an mRNA nucleic acid encoding a vaccine antigen, and comprise the ionizable cationic lipid in a total amount of 48-52 mol % of the total lipid content of the LNP composition at a N/P ratio of 4 to 7 relative to the mRNA nucleic acid, and the PEG-DMG in a total amount of 1.5 mol % of the total lipid content of the LNP composition.
